Skip to main content
. 2019 Aug 16;9:730. doi: 10.3389/fonc.2019.00730

Table 1.

Summary of characteristics of included studies.

Study ID T/C (n) Interventions Control Follow-up Baseline similarity Randomization Blinding Drop-off (%)
Chen (6) 20/20

  • 1. CHM fomula, 200 ml, po, BID, 8 weeks;

  • 2. Docetaxel, 70–100 mg/m2, ivgtt, day 1 and day 8, 21 days*2 courses;

  • 1. Cisplatin, 60 mg/m2, ivgtt, day 1 and day 8, 21 days*2 courses

  • 1. Docetaxel, 70–100 mg/m2, ivgtt, day 1 and day 8, 21 days*2 courses;

  • 2. Cisplatin, 60 mg/m2, ivgtt, day 1 and day 8, 21 days*2 courses

 Not reported Comparable (P > 0.05) Randomized Not reported 0
Chen (7) 30/29

  • 1. CHM fomula, 100 ml, po, BID, 18 days*2 courses;

  • 2. Taxol, 175 mg/m2, ivgtt, day 1, 21 days*2 courses;

  • 3. Carboplatin, 300 mg/m2, ivgtt, Day 2, 21 days*2 courses

  • 1. Taxol, 175 mg/m2, ivgtt, Day 1, 21 days*2 courses;

  • 2. Carboplatin, 300 mg/m2, ivgtt, Day 2, 21 days*2 courses

 Not reported Comparable (P > 0.05) Number randomized Not reported 1.7
Cheng and Zhang (8) 31/31

  • 1. CHM fomula, po, BID, 21 days;

  • 2. Pemetrexed, 500 mg/m2, ivgtt, Day 1, 1 course;

  • 3. Carboplatin, AUC = 5, ivgtt, Day 1, 1 course

  • 1. Pemetrexed, 500 mg/m2, ivgtt, Day 1, 1 course;

  • 2. Carboplatin, AUC = 5, ivgtt, Day 1, 1 course

 1 month Comparable (P > 0.05) Number randomized Not reported 0
Guo (9) 27/27

  • 1. Puerarin injection, 400 mg, ivgtt, QD, 21 days;

  • 2. Docetaxel, 75 mg/m2, ivgtt, Day 1, day 8, and day 15, 21 days*1–6 courses;

  • 3. Cisplatin, 30 mg/m2, ivgtt, Day 1–3, 21 days*1–6 courses

  • 1. Docetaxel, 75 mg/m2, ivgtt, Day 1, day 8, and day 15, 21 days*1–6 courses;

  • 2. Cisplatin, 30 mg/m2, ivgtt, Day 1–3, 21 days*1–6 courses

 Not reported Comparable (P > 0.05) Randomized Not reported 0
Han et al. (10) 25/25

  • 1. CHM fomula, 200 ml, po, BID, 21 days*3 courses;

  • 2. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*3 courses;

  • 3. Carboplatin, 300–500 mg/m2, ivgtt, Day 2, 21 days*3 courses

  • 1. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*3 courses;

  • 2. Carboplatin, 300–500 mg/m2, ivgtt, Day 2, 21 days*3 courses

 Not reported Comparable (P > 0.05) Randomized Not reported 0
Hao (11) 20/21

  • 1. CHM fomula, 200 ml, PO, BID, 3 weeks;

  • 2. Taxol, 135 mg/m2, ivgtt, 1 course;

  • 3. Carboplatin, AUC = 5, ivgtt, 1 course;

  • 1. Taxol, 135 mg/m2, ivgtt, 1 course;

  • 2. Carboplatin, AUC = 5, ivgtt, 1 course;

 Not reported Comparable (P > 0.05) Randomized Not reported 0
Li (12) 19/20

  • 1. CHM Capsule, 0.31 g *3, po, TID, 21 days*2 courses;

  • 2. Earthworm, 10 g, po, QD, 21 days*2 courses;

  • 3. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*2 courses;

  • 4. Carboplatin, AUC = 5, ivgtt, Day 1, 21 days*2 courses

  • 1. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*2 courses;

  • 2. Carboplatin, AUC = 5, ivgtt, Day 1, 21 days*2 courses

 Not reported Comparable (P > 0.05) Randomized Not reported 2.5
Li (13) 30/30

  • 1. CHM fomula, 200 ml, po, BID, 6 weeks;

  • 2. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*2 courses;

  • 3. Carboplatin, 75 mg/m2, ivgtt, Day 1, 21 days*2 courses

  • 1. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*2 courses;

  • 2. Carboplatin, 75 mg/m2, ivgtt, Day 1, 21 days*2 courses

 Not reported Comparable (P > 0.05) Randomized Not reported 0
Liu et al. (14) 30/30

  • 1. CHM fomula, 150 ml, po, BID, 4 weeks;

  • 2. Taxol, 135 mg/m2, ivgtt, Day 1, 1 course;

  • 3. Cisplatin, 75 mg/m2, ivgtt, Day 1, 1 course

  • 1. Taxol, 135 mg/m2, ivgtt, Day 1, 1 course;

  • 2. Cisplatin, 75 mg/m2, ivgtt, Day 1, 1 course

 Not reported Comparable (P > 0.06) Randomized Not reported 0
Ma (15) 15/15

  • 1. CHM fomula, 150 mg, po, BID, 8 weeks;

  • 2. Docetaxel, 135 mg/m2, ivgtt, Day 1, 21 days*2 courses;

  • 3. Cisplatin, 75 mg/m2, ivgtt, Day 1,21 days*2 courses

  • 1. Docetaxel, 135 mg/m2, ivgtt, Day 1, 21 days*2 courses;

  • 2. Cisplatin, 75 mg/m2, ivgtt, Day 1,21 days*2 courses

 Not reported Comparable (P > 0.05) Randomized Not reported 0
Mei (16) 20/20

  • 1. TCM fomula, 250 ml, po, BID, 6 weeks;

  • 2. Taxol, 135 mg/m2, ivgtt, Day 1, 3 weeks*2 courses;

  • 3. Cisplatin, 75 mg/m2, ivgtt, Day 1, 3 weeks*2 courses

  • 1. Taxol, 135 mg/m2, ivgtt, Day 1, 3 weeks*2 courses;

  • 2. Cisplatin, 75 mg/m2, ivgtt, Day 1, 3 weeks*2 courses

 Not reported Comparable (P > 0.05) Randomized Not reported 0
Qiu (17) 20/20

  • 1. CHM fomula, 100 ml, PO, BID, 21 days;

  • 2. Taxol, 135 mg/m2, ivgtt, Day 1, 1 course;

  • 3. Carboplatin, the dose according to patient, ivgtt, Day 2, 1 course;

  • 1. Taxol, 135 mg/m2, ivgtt, Day 1, 1 course;

  • 2. Carboplatin, the dose according to patient, ivgtt, Day 2, 1 course;

 Not reported Comparable (P > 0.05) Number table randomized Not reported 0
Zhao (18) 19/20

  • 1. CHM Capsule, 0.31 g *3, po, TID, 21 days*2 courses;

  • 2. Earthworm, 10 g, po, QD, 21 days*2 courses;

  • 3. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*2 courses;

  • 4. Carboplatin, AUC = 5, ivgtt, Day 1, 21 days*2 courses

  • 1. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*2 courses;

  • 2. Carboplatin, AUC = 5, ivgtt, Day 1, 21 days*2 courses

 Not reported Comparable (P > 0.05) Number table randomized Not reported 2.5
Jia (19) 42/42

  • 1. CHM fomula, 200 ml, po, BID, 6 months;

  • 2. Day 1–3, Docetaxel (60 mg/m2) + Cisplatin (50 mg/m2), ivgtt, From day 4, Docetaxel (90 mg/m2) + Cisplatin (60 mg/m2), IPT#, Once or twice a day, 6 months

 Days 1–3, Docetaxel(60 mg/m2) +Cisplatin (50 mg/m2), ivgtt, From day 4, Docetaxel (90 mg/m2) + Cisplatin (60 mg/m2), IPT#, Once or twice a day, 6 months 3 years Comparable (P > 0.05) Randomized Not reported 0
Yi et al. (20) 30/30

  • 1. CHM fomula, 100 ml, po, BID, 4 weeks;

  • 2. IL-2 (2 million U) + 0.9% NaCl (20 ml), Intraperitoneal perfusion, QW, 4 weeks

 IL-2 (2 million U) + 0.9%NaCl(20 ml), intraperitoneal perfusion, QW, 4 weeks Not reported Comparable (P > 0.05) Number table randomized Not reported 0 0
Mao et al. (21) 36/35

  • 1. CHM fomula 150 ml, po, BID, 30 days*6;

  • 2. Matrine Injection (4 ml) + Shenmai injection (50 ml), ivgtt, Day 1–9, Once per months, 6 months

 Matrine injection (4 ml) + Shenmai injection (50 ml), ivgtt, Day 1–9, Once per months, 6 months 6 months Comparable (P > 0.05) Randomized Not reported 0
Xu (22) 40/40

  • 1. TCM fomula, 100 ml, po, BID, 5 weeks;

  • 2. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*3 courses;

  • 3. Cisplatin, 75 mg/m2, ivgtt, Day 1, 21 days*3 courses

  • 4. Taxol + Cisplatin, 60 mg/m2, IPT#, once per course, 21 days*3 courses

  • 1. Taxol, 135 mg/m2, ivgtt, Day 1, 21 days*3 courses;

  • 2. Cisplatin, 75 mg/m2, ivgtt, Day 1, 21 days*3 courses

  • 3. Taxol + Cisplatin, 60 mg/m2, IPT#, once per course, 21 days*3 courses

 3 months Comparable (P > 0.05) Randomized Not reported 0
Zhang (23) 34/32

  • 1. CHM fomula, Accupoint application, QD, 1 week;

  • 2. Normal nursing

 Normal nursing Not reported Comparable (P > 0.05) Number table randomized Not reported 0
#

IPT, intraperitoneal perfusion chemotherapy.